New Delhi: The World Health Organization (WHO) on Friday released the emergency use list for the anti-Covid vaccine produced by Kovovax. Serum Institute of India under license novavaxExpanding the basket of jabs validated by the global health body against viral disease.
Serum Institute of India (SII) Chief Executive Officer (CEO) Adar Poonawalla described the WHO’s decision as “yet another milestone” in the fight against COVID-19.
Earlier this week, Poonawalla said that SII plans to launch Covovax in the next six months. He had said that Kovovax, which is under trial, would provide protection to children below three years of age as it had shown excellent data during trials.
“WHO released an emergency use list for Kovovax, expanding the basket of WHO-validated vaccines against Covid-19,” the world health body said in a tweet on Friday.
According to the WHO, Covovax is evaluated on the basis of a review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and construction site inspections conducted by the Drug Controller General of India (DCGI) as part of its emergency use inventory process. went.
“The Technical Advisory Group for the Emergency Use List, convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19, that the vaccine benefits are not any The risk is far greater, and that the vaccine can be used globally,” the tweet said.
Reacting to the development, Poonawalla tweeted, “This is yet another milestone in our fight against Covid-19, Kovovax now approved by WHO for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration…”
Serum Institute of India (SII) Chief Executive Officer (CEO) Adar Poonawalla described the WHO’s decision as “yet another milestone” in the fight against COVID-19.
Earlier this week, Poonawalla said that SII plans to launch Covovax in the next six months. He had said that Kovovax, which is under trial, would provide protection to children below three years of age as it had shown excellent data during trials.
“WHO released an emergency use list for Kovovax, expanding the basket of WHO-validated vaccines against Covid-19,” the world health body said in a tweet on Friday.
According to the WHO, Covovax is evaluated on the basis of a review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and construction site inspections conducted by the Drug Controller General of India (DCGI) as part of its emergency use inventory process. went.
“The Technical Advisory Group for the Emergency Use List, convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19, that the vaccine benefits are not any The risk is far greater, and that the vaccine can be used globally,” the tweet said.
Reacting to the development, Poonawalla tweeted, “This is yet another milestone in our fight against Covid-19, Kovovax now approved by WHO for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration…”
,